FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387472575> ?p ?o ?g. }

• W4387472575 endingPage "1337" @default.
• W4387472575 startingPage "1337" @default.
• W4387472575 abstract "Importance Universal nasal mupirocin plus chlorhexidine gluconate (CHG) bathing in intensive care units (ICUs) prevents methicillin-resistant S taphylococcus aureus (MRSA) infections and all-cause bloodstream infections. Antibiotic resistance to mupirocin has raised questions about whether an antiseptic could be advantageous for ICU decolonization. Objective To compare the effectiveness of iodophor vs mupirocin for universal ICU nasal decolonization in combination with CHG bathing. Design, Setting, and Participants Two-group noninferiority, pragmatic, cluster-randomized trial conducted in US community hospitals, all of which used mupirocin-CHG for universal decolonization in ICUs at baseline. Adult ICU patients in 137 randomized hospitals during baseline (May 1, 2015-April 30, 2017) and intervention (November 1, 2017-April 30, 2019) were included. Intervention Universal decolonization involving switching to iodophor-CHG (intervention) or continuing mupirocin-CHG (baseline). Main Outcomes and Measures ICU-attributable S aureus clinical cultures (primary outcome), MRSA clinical cultures, and all-cause bloodstream infections were evaluated using proportional hazard models to assess differences from baseline to intervention periods between the strategies. Results were also compared with a 2009-2011 trial of mupirocin-CHG vs no decolonization in the same hospital network. The prespecified noninferiority margin for the primary outcome was 10%. Results Among the 801 668 admissions in 233 ICUs, the participants’ mean (SD) age was 63.4 (17.2) years, 46.3% were female, and the mean (SD) ICU length of stay was 4.8 (4.7) days. Hazard ratios (HRs) for S aureus clinical isolates in the intervention vs baseline periods were 1.17 for iodophor-CHG (raw rate: 5.0 vs 4.3/1000 ICU-attributable days) and 0.99 for mupirocin-CHG (raw rate: 4.1 vs 4.0/1000 ICU-attributable days) (HR difference in differences significantly lower by 18.4% [95% CI, 10.7%-26.6%] for mupirocin-CHG, P &amp;lt; .001). For MRSA clinical cultures, HRs were 1.13 for iodophor-CHG (raw rate: 2.3 vs 2.1/1000 ICU-attributable days) and 0.99 for mupirocin-CHG (raw rate: 2.0 vs 2.0/1000 ICU-attributable days) (HR difference in differences significantly lower by 14.1% [95% CI, 3.7%-25.5%] for mupirocin-CHG, P = .007). For all-pathogen bloodstream infections, HRs were 1.00 (2.7 vs 2.7/1000) for iodophor-CHG and 1.01 (2.6 vs 2.6/1000) for mupirocin-CHG (nonsignificant HR difference in differences, −0.9% [95% CI, −9.0% to 8.0%]; P = .84). Compared with the 2009-2011 trial, the 30-day relative reduction in hazards in the mupirocin-CHG group relative to no decolonization (2009-2011 trial) were as follows: S aureus clinical cultures (current trial: 48.1% [95% CI, 35.6%-60.1%]; 2009-2011 trial: 58.8% [95% CI, 47.5%-70.7%]) and bloodstream infection rates (current trial: 70.4% [95% CI, 62.9%-77.8%]; 2009-2011 trial: 60.1% [95% CI, 49.1%-70.7%]). Conclusions and Relevance Nasal iodophor antiseptic did not meet criteria to be considered noninferior to nasal mupirocin antibiotic for the outcome of S aureus clinical cultures in adult ICU patients in the context of daily CHG bathing. In addition, the results were consistent with nasal iodophor being inferior to nasal mupirocin. Trial Registration ClinicalTrials.gov Identifier: NCT03140423" @default.
• W4387472575 created "2023-10-11" @default.
• W4387472575 creator A5000932721 @default.
• W4387472575 creator A5007885989 @default.
• W4387472575 creator A5010107447 @default.
• W4387472575 creator A5014967450 @default.
• W4387472575 creator A5016051838 @default.
• W4387472575 creator A5024645997 @default.
• W4387472575 creator A5026024349 @default.
• W4387472575 creator A5030171861 @default.
• W4387472575 creator A5032469870 @default.
• W4387472575 creator A5036433591 @default.
• W4387472575 creator A5037020908 @default.
• W4387472575 creator A5039641614 @default.
• W4387472575 creator A5042061244 @default.
• W4387472575 creator A5042543539 @default.
• W4387472575 creator A5042972207 @default.
• W4387472575 creator A5045532874 @default.
• W4387472575 creator A5045625549 @default.
• W4387472575 creator A5046304079 @default.
• W4387472575 creator A5047631181 @default.
• W4387472575 creator A5049632289 @default.
• W4387472575 creator A5052269702 @default.
• W4387472575 creator A5059962323 @default.
• W4387472575 creator A5063132605 @default.
• W4387472575 creator A5069073326 @default.
• W4387472575 creator A5071405748 @default.
• W4387472575 creator A5071711909 @default.
• W4387472575 creator A5075887798 @default.
• W4387472575 creator A5078300073 @default.
• W4387472575 creator A5081887623 @default.
• W4387472575 creator A5085146915 @default.
• W4387472575 creator A5089869042 @default.
• W4387472575 creator A5090116048 @default.
• W4387472575 date "2023-10-10" @default.
• W4387472575 modified "2023-10-14" @default.
• W4387472575 title "Nasal Iodophor Antiseptic vs Nasal Mupirocin Antibiotic in the Setting of Chlorhexidine Bathing to Prevent Infections in Adult ICUs" @default.
• W4387472575 cites W2005517409 @default.
• W4387472575 cites W2012919529 @default.
• W4387472575 cites W2014054175 @default.
• W4387472575 cites W2030012192 @default.
• W4387472575 cites W2057780602 @default.
• W4387472575 cites W2126768644 @default.
• W4387472575 cites W2127879007 @default.
• W4387472575 cites W2130837689 @default.
• W4387472575 cites W2134469459 @default.
• W4387472575 cites W2135399995 @default.
• W4387472575 cites W2141728850 @default.
• W4387472575 cites W2157715904 @default.
• W4387472575 cites W2171996179 @default.
• W4387472575 cites W2218892404 @default.
• W4387472575 cites W2346468312 @default.
• W4387472575 cites W2512525552 @default.
• W4387472575 cites W2911691098 @default.
• W4387472575 cites W2919520691 @default.
• W4387472575 cites W2969600894 @default.
• W4387472575 cites W2985777470 @default.
• W4387472575 cites W2991573081 @default.
• W4387472575 cites W3012868903 @default.
• W4387472575 cites W3036921559 @default.
• W4387472575 cites W3158901110 @default.
• W4387472575 cites W3188716630 @default.
• W4387472575 cites W3198731561 @default.
• W4387472575 cites W4230853241 @default.
• W4387472575 cites W4236100598 @default.
• W4387472575 cites W4241047482 @default.
• W4387472575 cites W4296122718 @default.
• W4387472575 doi "https://doi.org/10.1001/jama.2023.17219" @default.
• W4387472575 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37815567" @default.
• W4387472575 hasPublicationYear "2023" @default.
• W4387472575 type Work @default.
• W4387472575 citedByCount "0" @default.
• W4387472575 crossrefType "journal-article" @default.
• W4387472575 hasAuthorship W4387472575A5000932721 @default.
• W4387472575 hasAuthorship W4387472575A5007885989 @default.
• W4387472575 hasAuthorship W4387472575A5010107447 @default.
• W4387472575 hasAuthorship W4387472575A5014967450 @default.
• W4387472575 hasAuthorship W4387472575A5016051838 @default.
• W4387472575 hasAuthorship W4387472575A5024645997 @default.
• W4387472575 hasAuthorship W4387472575A5026024349 @default.
• W4387472575 hasAuthorship W4387472575A5030171861 @default.
• W4387472575 hasAuthorship W4387472575A5032469870 @default.
• W4387472575 hasAuthorship W4387472575A5036433591 @default.
• W4387472575 hasAuthorship W4387472575A5037020908 @default.
• W4387472575 hasAuthorship W4387472575A5039641614 @default.
• W4387472575 hasAuthorship W4387472575A5042061244 @default.
• W4387472575 hasAuthorship W4387472575A5042543539 @default.
• W4387472575 hasAuthorship W4387472575A5042972207 @default.
• W4387472575 hasAuthorship W4387472575A5045532874 @default.
• W4387472575 hasAuthorship W4387472575A5045625549 @default.
• W4387472575 hasAuthorship W4387472575A5046304079 @default.
• W4387472575 hasAuthorship W4387472575A5047631181 @default.
• W4387472575 hasAuthorship W4387472575A5049632289 @default.
• W4387472575 hasAuthorship W4387472575A5052269702 @default.
• W4387472575 hasAuthorship W4387472575A5059962323 @default.
• W4387472575 hasAuthorship W4387472575A5063132605 @default.
• W4387472575 hasAuthorship W4387472575A5069073326 @default.
• W4387472575 hasAuthorship W4387472575A5071405748 @default.

• next